NexaBiome is working to help move phage-based treatments closer to scalable, practical use for diabetic foot infections.

NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates. This gives them enhanced stability for use in a variety of applications which address two of the world's major challenges: antibiotic resistance and diabetic foot infections. By attaching specific bacteriophages to wound dressings and other substrates, we can reduce, augment or even substitute for antibiotics in human health. This lets us target disease-causing bacteria such as S. aureus, E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas and others. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations. Bacteriophages also have many potential human health applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.